成都欧林生物科技股份有限公司 2025 年第二次临时股东会会议资料 证券代码：688319 证券简称：欧林生物 成都欧林生物科技股份有限公司 2025 年第二次临时股东会会议资料 2025 年 11 月 成都欧林生物科技股份有限公司 2025 年第二次临时股东会会议资料 目 录 | 成都欧林生物科技股份有限公司 2025 年第二次临时股东会会议须知 2 | | --- | | 成都欧林生物科技股份有限公司 2025 年第二次临时股东会会议议程 4 | | 议案一：关于回购注销 2023 年限制性股票激励计划首次授予部分已获授尚未解除限售的第 | | 一类限制性股票的议案 7 | | 议案二：关于变更注册资本、修订《公司章程》并办理工商变更登记的议案 8 | | 议案三：关于公司发行境外上市股份（H 股）并在香港联合交易所有限公司上市的议案 .10 | | 议案四：关于公司发行境外上市股份（H 股）并在香港联合交易所有限公司上市方案的议案 | | 11 | | 议案五：关于公司转为境外募集股份并上市的股份有限公司的议案 15 | | 议案六：关于公司公开发行 H 股股票募集资金使用计划的议案 16 | | 议案 ...

Group 1 - The core point of the news is that Olin Bio has experienced a decline in stock price, dropping 0.35% to 22.49 CNY per share, with a total market value of 9.129 billion CNY and a cumulative drop of 10.36% over the last three days [1] - Olin Bio's main business involves the research, production, and sales of human vaccines, with the majority of revenue coming from the adsorbed tetanus vaccine at 90.99%, followed by A and C group meningococcal polysaccharide conjugate vaccine at 4.49%, and Hib conjugate vaccine at 3.99% [1] - The company was founded on December 11, 2009, and went public on June 8, 2021, located in Chengdu, Sichuan Province [1] Group 2 - Huafu Fund has a significant holding in Olin Bio, with its Huafu Health and Entertainment Flexible Allocation Mixed A Fund (001563) holding 600,000 shares, representing 7.56% of the fund's net value, making it the fourth-largest holding [2] - The fund has incurred a floating loss of approximately 48,000 CNY today and a total floating loss of 1.56 million CNY during the three-day decline [2] - The Huafu Health and Entertainment Flexible Allocation Mixed A Fund was established on August 4, 2015, with a current scale of 50.2705 million CNY and a year-to-date return of 41.01% [2]

Group 1 - On November 5, a total of 6 companies had their restricted shares unlocked, with a total unlock volume of 2.5094 million shares, amounting to a market value of approximately 92.0634 million yuan based on the latest closing price [1] - The companies with the highest unlock volumes were Airo Energy, Small Commodity City, and Wuxi Zhenhua, with unlock shares of 708,300, 698,700, and 539,000 respectively [1] - In terms of unlock market value, Airo Energy, Small Commodity City, and Wuxi Zhenhua also led, with market values of 52.837 million yuan, 12.1923 million yuan, and 11.9281 million yuan respectively [1] Group 2 - Regarding the proportion of unlock shares to total share capital, Airo Energy, Wuxi Zhenhua, and Meiansen had the highest unlock ratios, at 0.44%, 0.15%, and 0.11% respectively [1]

Core Viewpoint - The Chinese vaccine industry faces significant research and development challenges despite clear market demand, with companies like Olin Bio focusing on niche vaccine development to establish competitive advantages [4][12]. Group 1: Company Overview - Olin Bio, based in Chengdu, has dedicated 16 years to human vaccine research, successfully launching multiple products and achieving profitability within its first year of being listed on the STAR Market [4][8]. - The company has developed a strong focus on specialty vaccines, identifying unmet market needs in high-barrier areas, such as tetanus, and has achieved over 5 billion yuan in sales for its tetanus vaccine [4][8]. Group 2: Product Development - The tetanus vaccine was the first product developed, with sales growing from 12.52 million yuan in 2017 to 535 million yuan in 2024, reflecting a compound annual growth rate of 72.9% and maintaining over 85% market share in the external injury segment for eight consecutive years [8][9]. - Olin Bio is advancing its pipeline with a recombinant Staphylococcus aureus vaccine, which is currently in Phase III clinical trials, positioning the company as a leader in this critical area of vaccine development [10][11]. Group 3: Future Prospects - The company is also developing a Helicobacter pylori vaccine, which has received Phase I clinical approval in Australia, aiming to address a significant health challenge globally [12]. - Olin Bio's strategic focus on specialty vaccines is expected to enhance its market presence both domestically and internationally, contributing to public health safety [13].

Core Insights - The Chengdu-Chongqing economic circle is transitioning from strategic planning to practical implementation, with listed companies in the region driving high-quality development through innovation and practical efforts [1] Group 1: Company Goals and Strategies - Silicon Treasure Technology aims to become an internationally recognized brand in the silicone materials sector, targeting a revenue of 10 billion yuan by 2029 and striving for annual improvements in global industry rankings [2] - Olin Biotech is focused on continuous innovation to establish itself as a leading domestic and internationally recognized vaccine supplier, emphasizing the importance of patience and dedication in its development [3] - Chongqing Heavy Industry Holdings is developing a drone delivery system that will optimize logistics based on hospital orders, indicating a commitment to steady growth and technological advancement [4] - Reascent Technology is shifting its focus from being merely a materials supplier to providing high-standard, systematic "energy-saving, quiet, and dust-free" products for various spaces, reflecting the growing demand for clean air and high-quality living [5]

Summary of Key Points Core Viewpoint - The company announced the completion of a share reduction plan by its Vice President and Chief Financial Officer, which involved the sale of shares amounting to 0.0317% of the total share capital [1][4]. Group 1: Shareholding and Reduction Plan - Before the reduction plan, the Vice President, Mr. Tan Yong, held 571,440 shares, representing 0.14% of the total share capital, with 515,440 shares being tradable and 56,000 shares being restricted [1]. - The reduction plan was disclosed on September 5, 2025, with Mr. Tan planning to sell up to 128,860 shares within three months following the announcement [1]. - The actual reduction occurred between September 29, 2025, and October 31, 2025, where Mr. Tan sold 128,860 shares, leaving him with 442,580 shares, which is 0.1090% of the total share capital [1][4]. Group 2: Implementation Results - The reduction plan was fully implemented as per the disclosed plan, with no discrepancies between the planned and actual reductions [4]. - There were no early terminations of the reduction plan, confirming that it was executed as intended [4].

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 27.72 CNY, compared to the current stock price of 23.52 CNY [4]. Core Insights - The company reported a significant revenue increase of 31.11% year-on-year, reaching 507 million CNY in the first three quarters of 2025, with a remarkable net profit growth of 1079.36% to 47 million CNY [1]. - The company is leading globally in the clinical progress of its recombinant Staphylococcus aureus vaccine, with the Phase III clinical trial expected to unblind in the first half of 2026 [3]. - The company has optimized its expense ratio, resulting in a notable improvement in profitability, with a net profit margin increase of 9.32 percentage points to 9.30% [2]. Financial Performance - In Q3 2025, the company achieved a revenue of 201 million CNY, a year-on-year increase of 25.38%, and a net profit of 34 million CNY, up 7.22% [1]. - The gross profit margin for the first three quarters of 2025 was 93.10%, with a slight year-on-year decrease of 1.62 percentage points, while the expense ratio decreased by 13.08 percentage points to 79.30% [2]. - The company’s operating cash flow turned positive, reaching 33 million CNY in the first three quarters of 2025, compared to a negative cash flow of 6.2 million CNY in the same period of 2024 [1]. Research and Development - The company invested 143 million CNY in R&D during the first three quarters of 2025, accounting for 28.19% of its revenue, focusing on vaccines for "superbugs" and "adult vaccines" [4]. - The company is advancing multiple innovative vaccine pipelines, including a recombinant Helicobacter pylori vaccine and a recombinant Pseudomonas aeruginosa vaccine, among others [7]. Future Projections - Revenue growth is projected at 23.8%, 18.7%, and 15.2% for 2025, 2026, and 2027 respectively, with net profit growth expected at 224.7%, 20.1%, and 19.1% for the same years [7].

Company Summary - Olin Bio announced on November 3 that from September 29, 2025, to October 31, 2025, the company's Vice President and Chief Financial Officer, Mr. Tan Yong, reduced his shareholding by approximately 130,000 shares, accounting for 0.0317% of the company's total share capital. The reduction plan has been completed [1]

证券代码：688319 证券简称：欧林生物 公告编号：2025-061 成都欧林生物科技股份有限公司 一、减持主体减持前基本情况 1 高级管理人员减持计划完成暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 高级管理人员持股基本情况 本次减持计划实施前，公司副总经理、财务负责人谭勇先生持有公司股份 571,440 股，占公司总股本的比例为 0.14%。其中 515,440 股为无限售流通股， 来源为公司首次公开发行股票并上市前取得的股份以及非交易过户取得的股份， 56,000 股为限售流通股，来源为股权激励取得的股份。 公司于 2025 年 9 月 5 日在上海证券交易所网站（www.sse.com.cn）披露了 《成都欧林生物科技股份有限公司高级管理人员减持股份计划公告》（公告编号： 2025-045），谭勇先生计划通过集中竞价交易方式减持其持有的公司股份不超过 128,860 股，自减持股份计划公告披露之日起 15 个交易日后的 3 个月内实施。 减持计划的实施结果情况 2 ...

Market Overview - The biopharmaceutical sector experienced a slight decline of 0.0% on November 3, with Olin Bio leading the drop [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Top Performers - Sangfor Biopharma (688336) saw a significant increase of 7.88%, closing at 78.71 with a trading volume of 220,700 shares and a turnover of 1.754 billion yuan [1] - ST Weiming (002581) rose by 4.99%, closing at 8.20 with a trading volume of 82,400 shares [1] - Other notable gainers included C-Muyuan (688765) with a 3.61% increase, closing at 128.01, and Nossland (920047) with a 3.47% increase, closing at 27.41 [1] Underperformers - Olin Bio (688319) led the declines with a drop of 6.26%, closing at 23.52 and a trading volume of 126,900 shares [2] - Aopumai (688293) fell by 4.95%, closing at 58.82, while Hualan Vaccine (301207) decreased by 3.87%, closing at 21.10 [2] - Other significant losers included Changchun High-tech (000661) and Baiyin Suisi (301080), both experiencing declines of 3.60% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 155 million yuan from institutional investors, while retail investors contributed a net inflow of 227 million yuan [2] - The overall retail investor net outflow was 71.79 million yuan [2] Individual Stock Capital Flow - Rongchang Bio (688331) had a net inflow of 77.01 million yuan from institutional investors, representing 8.95% of its total [3] - Junshi Biosciences (688180) also saw a significant net inflow of 66.44 million yuan, accounting for 14.16% [3] - Olin Bio (688319) experienced a net outflow of 38.14 million yuan from retail investors, which was 14.13% of its total [3]